Revenue segments as reported by the company.

Software products and services

Drug discovery

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Sales and marketing

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Schrodinger 

Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. It operates through the Software and Drug Discovery business segments. The Software segment sells software to transform drug discovery across the life sciences industry and to customers in materials science industries. The Drug Discovery segment offers diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The company was founded by Richard A. Friesner, William A. Goddard, III and Murco Ringnalda in 1990 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Schrodinger reports robust revenue growth and eyes strategic expansion

Schrodinger delivered strong financial performance in 2022, driven by revenue growth in software and drug discovery segments.
The company's innovative pipeline advancements and focus on neuroscience therapeutics position it well for future growth.
While facing challenges in operating expenses and revenue projections, Schrodinger has opportunities for expansion through partnerships and customer growth.
Capitalizing on existing strengths and addressing challenges will be key for Schrodinger to sustain its growth trajectory and competitive edge.

Schrodinger (SDGR) reports robust Q1 performance and growth opportunities

Schrodinger (SDGR) had a strong Q1 2023, with revenue growth driven by software and drug discovery collaborations.
The company's balance sheet strengthened, but challenges exist with smaller biopharma revenue mix and customer acquisition.
Opportunities lie in capitalizing on existing customer loyalty, potential revenue growth, and continued investments in technology.
Overall, Schrodinger is well-positioned to leverage its strengths and address challenges to drive future growth.

Schrodinger meets revenue expectations, focuses on AI-driven drug discovery

Schrodinger's Q2 2023 earnings call highlighted solid revenue performance, ongoing software revenue discussions, and investments in R&D for platform development. The company showcased strengths in innovative drug discovery methods, progress on proprietary programs, and FDA clearances. Challenges include revenue fluctuations and uncertainties in revenue projections, while opportunities lie in expanding software contracts and leveraging AI for efficiency.

Schrodinger reports solid Q3 growth amidst expense challenges and opportunities

Schrodinger's Q3 performance showed revenue growth driven by software and drug discovery segments, despite increased expenses.
The company's focus on operational efficiency and proprietary programs positions it well for future growth and market expansion.
While facing challenges in managing expenses and uncertainties in partner priorities, Schrodinger remains committed to innovation and value creation.
Opportunities lie in scaling up software usage, evaluating collaboration programs, and leveraging customer interest for revenue growth.

Schrodinger reports strong revenue growth and strategic collaborations in 2023

Schrodinger's financial performance in 2023 reflects growth in total revenue and software revenue, driven by customer expansions and program advancements.
The company's strengths lie in its strategic focus on global biopharma companies, collaborations for AI tools, and the trend towards hosted contracts.
Challenges include forecasting revenue growth, decision-making on program advancement, and factors influencing software revenue dynamics.
Opportunities exist in the increased demand for computational tools, ongoing discussions for software adoption, and the validation of the platform through collaborations.

Schrodinger reports Q1 revenue growth amidst challenges and collaboration opportunities

Schrodinger's Q1 2024 performance reflects revenue growth driven by software revenue, though challenges in China and decreased gross margin were noted.
The company's strengths lie in regained rights to key inhibitors, promising pipeline advancements, and potential growth in ACV and collaboration opportunities.
While facing challenges in profitability and R&D expenses, Schrodinger is well-positioned to capitalize on opportunities in collaborations, funding, and drug development.
Overall, Schrodinger's strategic focus on innovation, partnerships, and pipeline advancement sets the stage for future growth and market expansion.

Schrodinger reports solid Q2 results, eyes strategic growth opportunities

Schrodinger's Q2 performance reflects steady revenue growth and margin improvement, despite operational challenges.
Strategic partnerships, acquisitions, and innovative solutions position Schrodinger for future expansion and market leadership.
Efforts to control expenses, drive revenue growth, and leverage market opportunities will be crucial for Schrodinger's long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Schrödinger, Inc. (NASDAQ:SDGR ) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Jaren Madden - Senior Vice President, Investor Relations and Corporate Affairs Ramy Farid - Chief Executive Officer Geoff Porges - Chief Financial Officer Karen Akinsanya - President of R&D, Therapeutics Conference Call Participants Do Kim - Piper Sandler David Lebowitz - Citi Gary Nachman - BMO Capital Markets Wolf Chanoff - Bank of America Operator Thank you for standing by. Welcome to Schrödinger's Conference Call to review Fourth Quarter and Full Year 2022 Financial Results.

Schrödinger, Inc. (SDGR) Q4 2022 Earnings Call Transcript

Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of 22% and 16.74%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Schrodinger, Inc. (SDGR) Reports Q4 Loss, Tops Revenue Estimates

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced financial results for the fourth quarter and full-year ended December 31, 2022, and provided its financial outlook for 2023.

Schrödinger Reports Strong Fourth Quarter and Full-Year 2022 Financial Results

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on February 15, 2023, the company granted non-statutory stock options to purchase an aggregate of 45,600 shares of the company's common stock to 11 newly hired employees, including two newly hired employees based outside of the United States.

Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Schrödinger Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported the receipt of an $111.3 million cash distribution from Nimbus Therapeutics, LLC (Nimbus) in connection with Takeda's acquisition of Nimbus Lakshmi, Inc., a wholly-owned subsidiary of Nimbus, and its tyrosine kinase 2 (TYK2) inhibitor NDI-034858.

Schrödinger Receives $111.3 Million Distribution from Sale of Nimbus's TYK2 Inhibitor to Takeda

NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its fourth quarter and full-year 2022 financial results on Tuesday, February 28, 2023, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed under "News & Events" in the investors section of Schrödinger's website, https://ir.

Schrödinger to Announce Fourth Quarter and Full-Year 2022 Financial Results on February 28

NEW YORK--( BUSINESS WIRE )--Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that management will participate in the SVB Securities Global Biopharma Conference and will give a presentation on Tuesday, February 14, 2023, at 1:00 p.m. ET.

Schrödinger to Present at SVB Securities Global Biopharma Conference

Schrodinger has developed a software platform that uses advanced physics and machine learning methods to predict important aspects of molecules with high accuracy. Their platform can help find new drugs faster and cheaper and increase the chances of success in further testing.

Schrodinger: Unlocking The Potential Of Computer-Assisted Drug Discovery During Tough Times

SDGR's valuable segment is its software business which represents majority of the revenue. There is an increasing demand for AI/ML capabilities by biopharmaceutical companies.

Schrodinger: Solving The Critical Need For AI/ML In The Biopharma Industry

NEW YORK--( BUSINESS WIRE )--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today provided an update on its progress across the business and announced its strategic priorities for 2023.

Schrödinger Provides Update on Progress Across the Business and Outlines 2023 Company Strategic Priorities

Incyte

Inspire Medical Systems Inc

Madrigal Pharmaceuticals

Veeva Systems

Verona Pharma

Viatris

With the healthcare sector poised to grow significantly in the coming years, healthcare stocks to buy present a fantastic opportunity for investors. Healthcare is something that everyone will need at some point in their lives, so today's industry of $8.3 trillion spent globally is an indication of a growing, profitable sector – one that could create many opportunities for those looking to make significant investments.

Why These 7 Healthcare Stocks Could Soar in 2023

Bionano Genomics

GlaxoSmithKline

iCAD

vTv Therapeutics

Choosing the best drug stocks to buy can be dicey because drug stocks have disadvantages and advantages. On the negative side, you often have to wait many years for promising drugs to prove themselves in clinical trials.

7 Drug Stocks That Will Soar in 2023

Schrodinger stock saw a good jump last week post Nimbus Takeda deal. In addition to immediate benefits, the deal also signals strong long-term prospects for the company's drug discovery collaboration business.

Schrodinger: Upgrading My Rating Post The Recent Nimbus Deal

NEW YORK--( BUSINESS WIRE )--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced new preclinical data on its potent and selective CDC7 inhibitor, SGR-2921, in a poster session at the American Society of Hematology (ASH) 64th Annual Meeting taking place virtually and in New Orleans, Louisiana. The data presented demonstrate that SGR-2921 exhibits strong anti-tumor activity in vivo across multiple acute myeloid leukemia (AML) models, including cell-derived xenograft models, as a monotherapy and in combination with standard of care agents. Moreover, SGR-2921 demonstrates anti-tumor activity in AML patient-derived samples resistant to standard of care agents.

Schrödinger Presents New Preclinical Data Supporting Advancement of CDC7 Inhibitor Development Candidate, SGR-2921, at American Society of Hematology 2022 Annual Meeting

Schrödinger's revenue is growing due to its consistent market share growth. The company's software platform is used by the company's multidisciplinary drug discovery team, and several biopharmaceutical and industrial companies.

Schrödinger: A Strong Player In The Field Of Drug Development Technology

NEW YORK--( BUSINESS WIRE )--Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that management will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference. The presentation will take place on Tuesday, November 29, 2022, at 4:00 p.m. ET.

Schrödinger to Present at Piper Sandler 34th Annual Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced that management will participate in the Jefferies 13th Annual London Healthcare Conference in London, UK.

Schrödinger to Present at Jefferies 13th Annual London Healthcare Conference

JinkoSolar Holding

During the current earnings season, a few of the companies whose stocks I own delivered great third-quarter results. These results, along with their other achievements, shows that the firms' technologies are being widely-embraced by end users.

3 Hypergrowth Stocks That Will Make You a Millionaire by 2027

Schrödinger, Inc. (NASDAQ:SDGR ) Q3 2022 Results Conference Call November 3, 2022 4:30 PM ET Company Participants Jaren Madden - SVP, IR and Corporate Affairs Ramy Farid - CEO Geoff Porges - CFO Karen Akinsanya - President, R&D, Therapeutics Conference Call Participants Do Kim - Piper Sandler David Lebowitz - Citi Gary Nachman - BMO Capital Markets Vikram Purohit - Morgan Stanley Gaurav Goparaju - Berenberg Capital Markets Operator Everyone, thank you for standing by. Welcome to Schrödinger Conference Call to review Third Quarter 2022 Financial Results.

Schrödinger, Inc. (SDGR) Q3 2022 Earnings Call Transcript

Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of 8.20% and 14.37%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Schrodinger, Inc. (SDGR) Reports Q3 Loss, Tops Revenue Estimates

NEW YORK--(BUSINESS WIRE)--Schrödinger today reported financial results for the third quarter of 2022 and provided an update on the company.

Schrödinger Reports Third Quarter 2022 Financial Results

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that new preclinical data on its CDC7 inhibitor, SGR-2921, will be presented during a poster session at the American Society of Hematology (ASH) 64th Annual Meeting taking place virtually and in New Orleans, Louisiana, December 10-13, 2022.

Schrödinger To Present New Preclinical Data From Its CDC7 Inhibitor Program At American Society Of Hematology 2022 Annual Meeting

NEW YORK--(BUSINESS WIRE)---- $SDGR--Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its third quarter 2022 financial results on Thursday, November 3, 2022, after the financial markets close.

Schrödinger to Announce Third Quarter 2022 Financial Results on November 3

NEW YORK--(BUSINESS WIRE)--Schrödinger is providing a detailed review of its technology platform during its Platform Day today, October 6, from 10:00 a.m. - 12:00 p.m. ET.

Schrödinger Hosts Platform Day

NEW YORK--(BUSINESS WIRE)---- $SDGR--Schrödinger announced that it will host Platform Day on October 6, 2022.

News for Schrodinger Stock (SDGR)